I thought you would pick that announcement up.
That's good to know that there was no court action involved. And what Dr. Mercer said ..... well, we know now that he did not quote from the Four Gospels.
The only odd thing about all that is another, earlier, announcement titled 'Update on VitroGro ECM' and dated January 30, 2013 - some 6 month earlier then the one you refer too. http://www.asx.com.au/asxpdf/20130130/pdf/42cnv750c50bcd.pdf
And I quote:
....
To recap the main points of the approval process:
1st bullet - that's a good one.
..... CE mark certificate would be issued shortly (ASX Announcement, 16 July 2012).
2nd bullet
.... review classification as Class III medical device rule 8 ....
3rd bullet
....should be regarded and assessed as Class III medical device Rule 13 ....
4th bullet
The MHRA ruling involved a requirement for the EMA to provide the Notified Body managing the approval process with a scientific opinion on the quality and safety of the product, taking into account the manufacturing process.
End of quote.
Maybe the company has got it mixed up - unintentional, of course.
Mixed up in the same way with all the delays encountered.
The only odd thing is that every delay was requested by the applicant - and that's Tissue Therapies - isnt' it? Not the BSI, the EMA, Big Pharma, Putin, the turf war, etc.......
You want proof - it's all in the thread about 'EMA fails to Follow...'. If you can't find it let me know and I shall send you the EMA document links where you can read it for yourself.
Re ASX Announcement 16 July 2012 - This is a well crafted announcement that may have to be taken as a work of fiction UNLESS the company is able to produce the relevant documents.
What Dr. Mercer said .... is simply not good enough.
Anyway, that's all cold coffee by now. Why you guys warm it up is beyond me.
